Efficacy of daptomycin lock therapy in the treatment of CRBSI

0

“Daptomycin (DPT) is an antibiotic active against Gram-positive bacteria with high bactericidal activity and good biofilm penetration.” Tatarelli et al (2014).

Reference:

Tatarelli, P., Parisini, A., Del Bono, V., Mikulska, M. and Viscoli, C. (2014) Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter. Infection. August 12th. [epub ahead of print].

Abstract:

BACKGROUND: Concomitant systemic and intracatheter antibiotic therapy is a therapeutic option for catheter-related bloodstream infections (CRBSI) in patient fitted with long-term intravenous central catheters. CRBSI are mainly caused by Gram-positive bacteria. Daptomycin (DPT) is an antibiotic active against Gram-positive bacteria with high bactericidal activity and good biofilm penetration.

OBJECTIVE: To study the efficacy of DPT given systemically and as lock therapy in the treatment of CRBSI.

MATERIALS AND METHODS: A retrospective review was conducted of adult patients with a long-term central venous catheter (CVC) receiving both systemic intravenous and intracatheter lock therapy for CRBSI. The primary outcome was catheter maintenance, following clinical success and microbiological eradication.

RESULTS: Eight patients who had failed previous standard therapy (vancomycin 7, cefazolin 1) were included in the study. In all but one, coagulase-negative staphylococci were repeatedly isolated. The other patient had enterococcal infection. DPT, given intravenously and as lock therapy, was successful in six of eight cases. The mean time to negative blood cultures was 2 days (range 1-6). In two cases neither clinical nor microbiological response was documented and the catheter was removed.

DISCUSSION: Systemic and intracatheter therapy with DPT is feasible, carries no toxicity and is apparently effective. DPT might be a suitable therapeutic option in CRBSI to achieve CVC sterilization and preserve the catheter.

Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).

Main page

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.